Liu Zhikun, Gao Feng, Shao Zhou, Xie Haiyang, Zhou Lin, Xu Xiao, Zheng Shusen
Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, China.
Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.
Gastroenterol Res Pract. 2017;2017:6353248. doi: 10.1155/2017/6353248. Epub 2017 Feb 27.
TFCP2 is an oncogene and plays crucial roles in the incidence and progression of hepatocellular carcinoma (HCC). However, no reports are available on the impact of TFCP2 genetic polymorphism on the susceptibility to and the transplant prognosis of HCC. Here, we genotyped 7 SNPs of TFCP2 in a case-control study of 119 patients with HCC and 200 patients with chronic liver disease. Of the 7 SNPs in TFCP2, rs7959378 distributed differentially between patients with versus patients without HCC. The patients with the CA (OR = 0.58, 95% CI = 0.35-0.96), the CC (OR = 0.39, 95% CI = 0.20-0.76), and the CA/CC (OR = 0.52, 95% CI = 0.32-0.83) genotypes had significantly decreased risk for HCC compared with those carrying the rs7959378 AA genotype. After adjusting for confounding factors, rs7959378 still conferred significant risk for HCC. Furthermore, the patients who carried rs7959378 AC/CC had a higher overall survival and lower relapse-free survival than those with the rs7959378 AA genotype. Similar results were found in the multivariate analysis adjusted by AFP, tumor size and tumor number, and differentiation. These findings indicate that rs7959378 is associated with the risk of HCC in patient with chronic liver disease and prognosis of HCC patients after liver transplantation.
TFCP2是一种癌基因，在肝细胞癌（HCC）的发生和发展中起关键作用。然而，关于TFCP2基因多态性对HCC易感性和移植预后影响的报道尚无。在此，我们在一项针对119例HCC患者和200例慢性肝病患者的病例对照研究中对TFCP2的7个单核苷酸多态性（SNP）进行了基因分型。在TFCP2的7个SNP中，rs7959378在HCC患者与非HCC患者之间分布存在差异。与携带rs7959378 AA基因型的患者相比，携带CA（比值比[OR]=0.58，95%置信区间[CI]=0.35 - 0.96）、CC（OR=0.39，95% CI=0.20 - 0.76）和CA/CC（OR=0.52，95% CI=0.32 - 0.83）基因型的患者患HCC的风险显著降低。在调整混杂因素后，rs7959378仍赋予HCC显著风险。此外，携带rs7959378 AC/CC的患者比携带rs7959378 AA基因型的患者总生存期更长，无复发生存期更短。在经甲胎蛋白（AFP）、肿瘤大小、肿瘤数量和分化情况调整的多变量分析中也发现了类似结果。这些发现表明，rs7959378与慢性肝病患者的HCC风险以及肝移植后HCC患者的预后相关。
